Serum biomarkers in valvular heart disease

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Heart

• Publication date

  2017-09-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/heartjnl-2016-310482PMID 28928243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Replicated, Genome-Wide Significant Association of Aortic Stenosis With a Genetic Variant for Lipoprotein(a): Meta-Analysis of Published and Novel Data.

  2017cited by this paper
• Oxidized Phospholipids, Lipoprotein(a), and Progression of Calci fi c Aortic Valve Stenosis

  2017cited by this paper
• Calcific aortic stenosis

  2016cited by this paper
• The effect of statins therapy in aortic stenosis: Meta-analysis comparison data of RCTs and observationals

  2016cited by this paper
• Impact of Serial B-Type Natriuretic Peptide Changes for Predicting Outcome in Asymptomatic Patients With Aortic Stenosis.

  2016cited by this paper
• Natural History, Diagnostic Approaches, and Therapeutic Strategies for Patients With Asymptomatic Severe Aortic Stenosis.

  2016cited by this paper
• Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study.

  2016cited by this paper
• Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment

  2016cited by this paper
• Galectin-3 in cardiac muscle and circulation of dogs with degenerative mitral valve disease.

  2016cited by this paper
• Patients with calcific aortic stenosis exhibit systemic molecular evidence of ischemia, enhanced coagulation, oxidative stress and impaired cholesterol transport.

  2016cited by this paper
• Calcific aortic stenosis

  2016cited by this paper
• Targeting the tricuspid valve: A new therapeutic challenge.

  2016cited by this paper
• Determinants and prognostic value of Galectin-3 in patients with aortic valve stenosis

  2016cited by this paper
• Association of B-Type Natriuretic Peptide With Survival in Patients With Degenerative Mitral Regurgitation.

  2016cited by this paper
• Role for Galectin‐3 in Calcific Aortic Valve Stenosis

  2016cited by this paper
• The modern epidemiology of heart valve disease

  2015cited by this paper
• Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies

  2015cited by this paper
• Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement

  2015cited by this paper
• A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis

  2015cited by this paper
• Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.

  2015cited by this paper
• MicroRNA-125b and chemokine CCL4 expression are associated with calcific aortic valve disease

  2015cited by this paper
• Beyond the Limits: Clinical Utility of Novel Cardiac Biomarkers

  2015cited by this paper
• Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium.

  2015cited by this paper
• Elevated Plasma Soluble ST2 Is Associated with Heart Failure Symptoms and Outcome in Aortic Stenosis

  2015cited by this paper
• MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest?

  2015cited by this paper
• The Association between Job Strain and Atrial Fibrillation: Results from the Swedish WOLF Study

  2015cited by this paper
• The Affymetrix DMET Plus Platform Reveals Unique Distribution of ADME-Related Variants in Ethnic Arabs

  2015cited by this paper
• Cardiac Biomarkers

  2015cited by this paper
• Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy.

  2015cited by this paper
• Midregional-proAtrial Natriuretic Peptide and High Sensitive Troponin T Strongly Predict Adverse Outcome in Patients Undergoing Percutaneous Repair of Mitral Valve Regurgitation

  2015cited by this paper
• Circulating microRNA Profiling Needs Further Refinement Before Clinical Use in Patients With Aortic Stenosis

  2015cited by this paper
• Tissue Velocities and Myocardial Deformation in Asymptomatic and Symptomatic Aortic Stenosis.

  2015cited by this paper
• The role of cardiac biomarkers in cardiovascular disease risk assessment

  2014cited by this paper
• High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis

  2014cited by this paper
• B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival.

  2014cited by this paper
• Left Ventricular Hypertrophy With Strain and Aortic Stenosis

  2014cited by this paper
• Incremental Prognostic Value of Left Ventricular Global Longitudinal Strain in Patients With Aortic Stenosis and Preserved Ejection Fraction

  2014cited by this paper
• Emerging Biomarkers in Heart Failure and Cardiac Cachexia

  2014cited by this paper
• Galectin-3 predicts short- and long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI).

  2014cited by this paper
• microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation.

  2014cited by this paper
• Guidelines on the Management of Valvular Heart disease (Version 2012)

  2013cited by this paper
• Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening

  2013cited by this paper
• Preprocedural high-sensitive troponin predicts survival after transcatheter aortic valve implantation (TAVI).

  2013cited by this paper
• High-sensitivity troponin T is a prognostic marker for patients with aortic stenosis after valve replacement surgery.

  2013cited by this paper
• Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients.

  2013cited by this paper
• Genetic associations with valvular calcification and aortic stenosis.

  2013cited by this paper
• GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men

  2013cited by this paper
• Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals.

  2013cited by this paper
• Growth differentiation factor 15: a novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients.

  2013cited by this paper
• Circulating Levels of miR‐133a Predict the Regression Potential of Left Ventricular Hypertrophy After Valve Replacement Surgery in Patients With Aortic Stenosis

  2013cited by this paper
• Guidelines on the management of valvular heart disease (version 2012).

  2012cited by this paper
• Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance

  2012cited by this paper
• Determinants and Prognostic Significance of Exercise Pulmonary Hypertension in Asymptomatic Severe Aortic Stenosis

  2012cited by this paper
• Circulating growth differentiation factor‐15 correlates with myocardial fibrosis in patients with non‐ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support

  2012cited by this paper
• Frequency, Determinants and Outcome of Pulmonary Hypertension in Patients With Aortic Valve Stenosis

  2012cited by this paper
• Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum

  2012cited by this paper
• Cardiac biomarkers: new tools for heart failure management.

  2012cited by this paper
• Growth differentiation factor 15, ST2, high‐sensitivity troponin T, and N‐terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction

  2012cited by this paper
• Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

  2012cited by this paper
• Comparison of atrial and brain natriuretic peptide for the assessment of mitral stenosis.

  2011cited by this paper
• Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy.

  2011cited by this paper
• Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis.

  2011cited by this paper
• MicroRNA therapeutics in cardiovascular medicine

  2011cited by this paper
• Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry.

  2011cited by this paper
• Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis

  2010cited by this paper
• Valvular heart disease: diagnosis and management.

  2010cited by this paper
• Prospective Validation of the Prognostic Usefulness of Brain Natriuretic Peptide in Asymptomatic Patients With Chronic Severe Mitral Regurgitation

  2010cited by this paper
• The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction

  2010cited by this paper
• Risk stratification in asymptomatic moderate to severe aortic stenosis: the importance of the valvular, arterial and ventricular interplay

  2010cited by this paper
• B-Type Natriuretic Peptide in Isolated Severe Tricuspid Regurgitation: Determinants and Impact on Outcome

  2010cited by this paper
• Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction >60%.

  2010cited by this paper
• Valvular heart disease: the next cardiac epidemic

  2010cited by this paper
• Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chronic severe aortic regurgitation.

  2009cited by this paper
• Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation.

  2009cited by this paper
• Risk Score for Predicting Outcome in Patients With Asymptomatic Aortic Stenosis

  2009cited by this paper
• Diagnostic and prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients with chronic aortic regurgitation.

  2008cited by this paper
• Association of Fetuin-A With Mitral Annular Calcification and Aortic Stenosis Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study

  2007cited by this paper
• The relationship between the level of plasma B-type natriuretic peptide and mitral stenosis

  2007cited by this paper
• Echocardiographic and hemodynamic findings in patients with mitral stenosis undergoing percutaneous mitral commissurotomy comparing those with chronic atrial fibrillation versus those with normal sinus rhythm.

  2007cited by this paper
• MicroRNA Expression Signature and Antisense-Mediated Depletion Reveal an Essential Role of MicroRNA in Vascular Neointimal Lesion Formation

  2007cited by this paper
• Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study.

  2007cited by this paper
• B-type natriuretic peptide and left ventricular dysfunction on exercise echocardiography in patients with chronic aortic regurgitation

  2007cited by this paper
• Global systems biology, personalized medicine and molecular epidemiology

  2006cited by this paper
• The Transforming Growth Factor-&bgr; Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury

  2006cited by this paper
• Pathology of inflammatory native valvular heart disease.

  2006cited by this paper
• Hemodynamic characteristics and progression to heart failure in regurgitant lesions.

  2006cited by this paper
• Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery.

  2005cited by this paper
• Quantitative determinants of the outcome of asymptomatic mitral regurgitation.

  2005cited by this paper
• B-Type Natriuretic Peptide in Organic Mitral Regurgitation: Determinants and Impact on Outcome

  2005cited by this paper
• Natriuretic Peptides Predict Symptom-Free Survival and Postoperative Outcome in Severe Aortic Stenosis

  2004cited by this paper
• Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction

  2004cited by this paper
• Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation.

  2003cited by this paper
• Cardiac troponin I in aortic valve disease.

  2003cited by this paper
• Functional Changes in Coronary Microcirculation After Valve Replacement in Patients With Aortic Stenosis

  2003cited by this paper
• Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation.

  2003cited by this paper
• Contemporary approach to aortic and mitral regurgitation.

  2003cited by this paper
• Increased Plasma Natriuretic Peptide Levels Reflect Symptom Onset in Aortic Stenosis

  2003cited by this paper
• Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms

  2003cited by this paper
• Mechanisms of Coronary Microcirculatory Dysfunction in Patients With Aortic Stenosis and Angiographically Normal Coronary Arteries

  2002cited by this paper
• Metabonomics: a platform for studying drug toxicity and gene function

  2002cited by this paper

• Blood biomarkers in left-sided valvular heart disease.

  2025cites this paper
• Strategic Reduction of Hybrid Insulin Peptide Formation Significantly Delays Diabetes Onset in NOD Mice.

  2025cites this paper
• Transcatheter treatment of the tricuspid valve: current status and perspectives.

  2024cites this paper
• Could Renin-angiotensin System Inhibitors Reduce Fibrosis in Rheumatic Heart Disease by Inhibiting Soluble Suppression of Tumorigenicity 2 (sST2)?: Systematic Review

  2024cites this paper
• Correlation of n-terminal pro-brain-type natriuretic peptide levels with the severity of single mitral regurgitation or accompanied by mild aorta valve dysfunction in patients with rheumatic heart disease in Sanglah general hospital.

  2023cites this paper
• Increased NT-proBNP levels and cardiac ventricular function during aortic valve replacement (pilot study)

  2023cites this paper
• Concomitant Hepatorenal Dysfunction and Malnutrition in Valvular Heart Surgery: Long‐Term Prognostic Implications for Death and Heart Failure

  2022cites this paper
• Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology

  2022cites this paper
• Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: the RamiRHeD trial protocol

  2021cites this paper
• Cardiac Biomarkers and Prediction of Early Outcome After Heart Valve Surgery: A Prospective Observational Study.

  2021cites this paper
• Time-resolved fluorescence resonance energy transfer-based lateral flow immunoassay using a raspberry-type europium particle and a single membrane for the detection of cardiac troponin I.

  2020cites this paper
• Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide in Elderly Patients With Valvular Heart Disease.

  2020cites this paper
• Relationship between B‐type natriuretic peptide and invasive haemodynamics in patients with severe aortic valve stenosis

  2020cites this paper
• High-sensitivity troponin T in asymptomatic severe aortic stenosis

  2019cites this paper
• Metabolic risk markers and relative survival in patients with aortic stenosis requiring surgery

  2019cites this paper
• Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis.

  2019cites this paper
• Multiple biomarker panel to screen for severe aortic stenosis: results from the CASABLANCA study

  2018cites this paper
• Heartbeat: Transcatheter procedures for secondary mitral regurgitation?

  2018cites this paper